2-氯嘌呤 | 1681-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 2-氯嘌呤
• 中文别名: 一缩二乙二醇一(2-乙基已基)醚；二甘醇(2-乙己基)醚；2-乙己基卡必醇；二甘醇一(2-乙己基)醚；二乙二醇单辛醚；一缩二乙二醇单(2-乙基已基)醚；2-{(2-[(2-乙基己基)氧基]乙氧基}乙醇；二甘醇单(2-乙己基)醚
• 英文名称: 2-chloro-9H-purine
• 英文别名: 2-Chlor-purin；2-chloropurine；2-chloro-7H-purine
• CAS: 1681-15-8
• 化学式: C₅H₃ClN₄
• mdl: MFCD00137826
• 分子量: 154.559
• InChiKey: JBMBVWROWJGFMG-UHFFFAOYSA-N

物化性质

• 熔点：
  231-234 °C
• 沸点：
  287.9±23.0 °C(Predicted)
• 密度：
  1.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-7h-purine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-7h-purine
CAS number: 1681-15-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H3ClN4
Molecular weight: 154.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯嘌呤 以 甲醇 、 乙醚 为溶剂， 反应 99.5h， 生成 2-Methoxy-9-methylpurine
  参考文献：
  名称：

  The preparation and 1H n.m.r. spectra of some N-methylpurines and related compounds

  摘要：

  一些甲氧基、甲硫基和氯-N-甲基嘌呤及 对一些甲氧基、甲硫基和氯-N-甲基嘌呤以及咪唑并[4,5-c]-吡啶的 1H nm r 研究发现，当 N-甲基出现在六元环上时，其信号的场强比出现在咪唑环上时低。 六元环上的 N-甲基所产生的信号场低于咪唑环上的 N-甲基所产生的信号场。2-、6-和 8-甲氧基嘌呤的甲基化 和 2-、6-和 8-甲氧基嘌呤与重氮甲烷的甲基化反应，以及氯-N-甲基嘌呤与甲氧基-N-甲基嘌呤的甲基化反应。 介绍。

  DOI：

  10.1071/ch9830633
• 作为产物：
  描述：

  2-氯-6-肼基-9h-嘌呤 在 水 、 氧气 、 copper(II) sulfate 作用下， 反应 6.0h， 以75%的产率得到2-氯嘌呤
  参考文献：
  名称：

  Efficient synthesis of nebularine and vidarabine via dehydrazination of (hetero)aromatics catalyzed by CuSO₄in water

  摘要：

  首次在催化量的CuSO4存在下实现了一步简单的脱氢反应。以CuSO4 (2 mol%)为催化剂，水为溶剂，脱氢产物获得了良好的产率（66-95%）。此外，成功合成了药物 nebularine 和 Vidarabine，并且 Vidarabine 可在0.923公斤规模生产，显示出良好的工业应用潜力。

  DOI：

  10.1039/c3gc41658e
• 作为试剂：
  描述：

  3-(3-benzyloxy-4-methoxy-benzyl)-8-isopropyl-hypoxanthine 、 三氯氧磷 、 氨 、 盐酸 在 甲苯 、 2-氯嘌呤 、 四氢呋喃 、 crude product 作用下， 以 甲醇 为溶剂， -30.0~70.0 ℃ 、312.54 MPa 条件下， 反应 3.58h， 以to give 6-amino-3-(3-benzyloxy-4-methoxy-benzyl)-8-isopropyl-3H-purine hydrochloride (4.04 g, 91.8%)的产率得到3-[(4-methoxy-3-phenylmethoxyphenyl)methyl]-8-propan-2-ylpurin-6-amine;hydrochloride
  参考文献：
  名称：

  Purine derivatives having phosphodiesterase IV inhibition activity

  摘要：

  公开的是式(I)的化合物：其中，R3选自C1-10烷基，C1-10烯基，C3-10环烷基，C4-10环烷基烷基或C3-10环烯基的群，其中，所述烷基，烯基，环烷基，环烷基烷基或环烯基在一个位置上可以用羟基取代；或苄基，其中，所述苄基在一个或两个位置上可以用卤素，烷氧基，环烷氧基或多环烷基取代，其中，所述烷氧基或环烷氧基的烷基部分在一个位置上可以用羟基取代；R8选自氢，C1-10烷基，C1-10烯基，C3-10环烷基，C4-10环烷基烷基或C3-10环烯基的群，其中，所述烷基，烯基，环烷基，环烷基烷基或环烯基在一个位置上可以用羟基取代；或苄基，其中，所述苄基在一个或两个位置上可以用卤素，烷氧基，环烷氧基或多环烷基取代，其中，所述烷氧基或环烷氧基的烷基部分在一个位置上可以用羟基取代；R6a和R6b独立地选自氢，C1-10烷基，C1-10烯基，C3-10环烷基，C4-10环烷基烷基或C3-10环烯基的群，其中，所述烷基，烯基，环烷基，环烷基烷基或环烯基在一个位置上可以用羟基取代；以及其药学上可接受的盐。

  公开号：

  US06228859B1

文献信息

• [EN] TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS TRICYCLIQUES INHIBITEURS DE PI3K ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012082997A1

  公开（公告）日：2012-06-21

  Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

  具有抗癌活性、抗炎活性或免疫调节特性的Formula I的三环PI3K抑制剂化合物被描述。描述了使用Formula I的三环PI3K抑制剂化合物进行体外、原位和体内诊断或治疗哺乳动物细胞、生物体或相关病理条件的方法。Formula I化合物包括立体异构体、几何异构体、互变异构体和其药用可接受盐。虚线表示可选的双键，至少有一条虚线是双键。取代基如所述。
• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• Visible Light-Promoted Aliphatic C–H Arylation Using Selectfluor as a Hydrogen Atom Transfer Reagent
  作者：Hong Zhao、Jian Jin

  DOI：10.1021/acs.orglett.9b01635

  日期：2019.8.16

  A mild, practical method for direct arylation of unactivated C(sp3)–H bonds with heteroarenes has been achieved via photochemistry. Selectfluor is used as a hydrogen atom transfer reagent under visible light irradiation. A diverse range of chemical feedstocks, such as alkanes, ketones, esters, and ethers, and complex molecules readily undergo intermolecular C(sp3)–C(sp2) bond formation. Moreover, a

  通过光化学已经实现了一种温和的，实用的方法，用于将未激活的C（sp 3）–H键与杂芳烃直接芳基化。Selectfluor在可见光照射下用作氢原子转移试剂。各种各样的化学原料，例如烷烃，酮，酯和醚，以及复杂的分子容易形成分子间的C（sp 3）–C（sp 2）键。此外，可通过此处介绍的方案有效地烷基化各种杂芳烃，包括药学上有用的支架。
• [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009053716A1

  公开（公告）日：2009-04-30

  This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  这项发明提供了一种化合物，其为式(Ia)或(Ib)的嘌呤类化合物：及其药学上可接受的盐，这些化合物是PI3K的抑制剂，并且对p110δ同工型具有选择性，p110δ是Ia类PI3激酶，优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱，如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
• [EN] PYRAZOLYLAMINOPURINES AS ITK INHIBITORS<br/>[FR] PYRAZOLYLAMINOPURINES EN TANT QU'INHIBITEURS DE LA TYROSYNE KINASE (ITK)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016091916A1

  公开（公告）日：2016-06-16

  Provided are pyrazolylaminopurine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula I or II, stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R4, R5, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

  提供了一种抑制ITK激酶的吡唑基氨基嘌呤化合物，包含这些化合物的组合物以及治疗由ITK激酶介导的疾病的方法。具体来说，提供了符合式I或II的化合物，立体异构体，互变异构体，溶剂合物，前药或其药用可接受的盐，其中n，R1，R2，R3，R4，R5，R6和R7在此处定义，包含该化合物和药用可接受的载体的药物组合物，使用该化合物或组合物进行治疗的方法，例如，用于治疗患有由ITK激酶介导的疾病或病况的患者。

表征谱图